Skip to content

Evaluation of the effect of rTMS on nicotine craving

Evaluation of the effect of rTMS on nicotine in patients with schizophrenia: a double-blind clinical trial study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201219049768N1
Enrollment
44
Registered
2024-09-24
Start date
2021-01-20
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking disorder in patients with schizophrenia. Nicotine dependence

Interventions

Intervention 1: Intervention group: Patients in the intervention group will undergo repetitive transcranial magnetic stimulation (rTMS) treatment in ten sessions (two weeks, with five sessions per wee

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Confirmation of the diagnosis of schizophrenia based on DSM-5 and according to a clinical interview conducted by a faculty psychiatrist Confirmation of the diagnosis of smoking disorder based on DSM-5 and according to a clinical interview conducted by a faculty psychiatrist Do not take clozapine Age 18 to 60 years No dependence on alcohol and other substances except nicotine Lack of criteria for other substance use disorders in the last three months Absence of clinical contraindications on rTMS such as metal, shunt or implant in the brain, history of brain surgery, increased intracranial pressure, pregnancy or attempt to conceive, history of seizures in the person and the presence of a pacemaker

Exclusion criteria

Exclusion criteria: Receive ECT at the same time

Design outcomes

Primary

MeasureTime frame
Number of cigarettes smoked. Timepoint: Before and immediately after the intervention and one month later. Method of measurement: Question from the patient.;Craving for nicotine. Timepoint: Before and immediately after the intervention. Method of measurement: Visual Analogue Scale.

Secondary

MeasureTime frame
Severity of positive and negative symptoms of schizophrenia. Timepoint: Before and immediately after the intervention. Method of measurement: Positive and negative syndrome scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnaz Zare Mehrjardi

Iran University of Medical Sciences

golizar90@yahoo.com+98 21 4437 6509

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026